Abstract Details

Title Thalamic Atrophy Is Associated with Development of Clinically Definite MS

Topic MS and Related Diseases

Presentation(s) S51 - (-)

Poster/Presentation
Number 004

Objective

Background Gray matter (GM) damage has an important role in disease progression of patients with MS.

Design/Methods 216 CIS patients who participated in multi-center Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study) were assessed with MRI at baseline, 6 months, 1 and 2 years. Patients were evaluated within 4 months of initial demyelinating event, had 2 or more brain MRI lesions and the presence of 2 or more oligoclonal bands in cerebrospinal fluid. The MRI measures of progression included cumulative number and volume of contrast enhancing and new and enlarging T2-lesions, and changes in whole brain and tissue-specific global and regional GM volumes.

Results Over 2 years, 92 of 216 patients (42.6%) converted to CDMS. The mean time to first relapse was 3.1 months and mean annual relapse rate was 0.46. In mixed effect model analysis, thalamic volume showed the most significant decrease in CDMS (p<0.0001), followed by increase in lateral ventricle (p=0.0007), decrease in whole brain (p=0.005) and a trend for decrease in cortical volumes (p=0.035) compared to stable CIS patients over 2 years. In multivariate regression analysis, decrease in thalamic and increase in lateral ventricle volumes (p<0.0001) were the only MRI measures associated with development of CDMS, whereas the cumulative number of new T2 or CE lesions was not retained in the model.

Conclusions Development of thalamic and central atrophy is associated with conversion to CDMS over 2 years. Use of these MRI biomarkers may be relevant for identifying patients at high risk for conversion to CDMS in future clinical trials involving CIS patients.

Authors/Disclosures
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) PRESENTER	The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Eva Havrdova, MD (Neurologicka Klinika 1 LF UK)	Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)	Prof. Bergsland has nothing to disclose.
Michaela Tyblova (Nurologicka Klinika 1 LF UK)	No disclosure on file
Jesper Hagemeier	No disclosure on file
	No disclosure on file
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center)	Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Manuela Vaneckova	Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Manuela Vaneckova has received research support from Czech Ministry of Health project—grants NU 22-04-00193 . Manuela Vaneckova has received research support from Czech Ministry of Health project - RVO VFN 64165 . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving as a principal investigator with Czech Ministry of Health project—grants NU 22-04-00193 .
Jan Krasensky, MD	No disclosure on file
Ellen Carl, MS (The Jacobs Neurological Institute)	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��